65,437 trials
Diabetic Autonomic Neuropathy
Primary: Change in E/I Ratio From Baseline to Endpoint After 24 Weeks of Intervention With Bromocriptine QR vs Placebo — -0.02; -0.05 E/I ratio change — p=0.603
Suicide
Primary: Veteran Suicidal Ideation — 1.50; 3.50; 1.00; 3.38 units on a scale — p=.03
Abdominal Aortic Aneurysm
Primary: Number of Subjects With Proximal Type I Endoleak — 2 Participants
Acute Otitis Media
Primary: The Rate of Occurrence of Acute Otitis Media (AOM) Episodes Per Child-Year — 1.48; 1.56 Occurrences per child-year — p=0.66
Vitiligo
Primary: Percentage of Participants Treated With Ruxolitinib Cream Who Achieved a ≥ 50% Improvement From Baseline in Facial Assessment of the Vitiligo Area and Severity Index…
Dry Eye Syndrome · Keratoconjunctivitis Sicca
Primary: Number of Subjects With a ≥10 mm Increase From Baseline in Schirmer Tear Test (STT) — 12; 10; 13; 6 participants — p=0.1352
COVID-19
Primary: Incidence of Mortality — 32; 26 Participants — p=0.1885
Neonatal Respiratory Distress Syndrome · Extremely Low Birth Weight Infant (ELBW) · BronchoPulmonary Dysplasia
Primary: Number of Participants With Successful Wean Off CPAP at the First Attempt — 31; 30 Participants
Endometrial Cancer
Primary: Percentage of Participants With Positive Predictive Value and Negative Predictive Value From Fluorescein Visualization — 71; 100; 85; 90 percentage of participants
Locally Advanced or Metastatic Pancreatic Cancer
Primary: Overall Tumor Response Rate (ORR) — 4.0; 9.5 percentage of participants
Pyruvate Kinase Deficiency · Anemia, Hemolytic
Primary: Percentage of Participants Achieving a Reduction in Transfusion Burden in Part 2 — 37 percentage of participants — p=0.0002
Liver Transplant · Kidney Transplant
Primary: Tacrolimus Target Trough Level Maintenance — 38.4; 24.2 percentage of days
Recurrent Pleural Malignant Mesothelioma · Stage IV Pleural Mesothelioma
Primary: Progression-free Survival (PFS) — 1.8 months
Schizophrenia
Primary: Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set — 53; 13; 23 Participants — p=<0.0001
Melanoma
Primary: Number of Participants With Optimal Biological Dose (OBD) of LL37 Based Upon Toxicity — 2; 1 Participants